#118185
Re: Farmas USA
ACST
Buen dia para todos por aqui
framus . al final aunque no lo parecia, pero se comporto como Doble techo , el AT es asi
mugi . mi opinion , manipulacion total , tenian un ATM en marcha y necesitan fondos, la pumpearon por todos lados, un descaro mas
0tra probabilidad-- Los Trilogy 1 y 2 han sido exitosos, ,conviene soltar los dos read out a la vez , y unos pejes gordos quieren entrar a precios muy atractivos, entonces interesa , el delay con su consecuente sell off, inventos mios claro.
Yo, en cuanto defina suelo, re compro la mitad que solte a 2.50 y me apunto al segundo rally que de aqui a finales de enero debe haber , probablemente espere la correccion del SP que espero para enero tambien para hacer esa re compra , y de ser asi , a saco pues si o si rally ACST de aqui a finales de enero vamos a tener, La mitad que me quedo le voy a poner un SLoss en breakeven y si se vende y luego baja mas re compro otra vez
Sigo pensando que aunque tal vez no sea mejor que Vascepa ni tiene aun los estudios de esta para competir pero la molecula del Ac Krilll funciona ,hace años esta en el mercado de forma impirica y con buena biotolerancia, pero le queda mucho camino a ACST entonces ,asi que me apunto a largo, Plan Inversor y cada vez que se pueda a tradear
Mas opiniones se agradecen tambien
-----------.
- Topline results will include a readout of the primary endpoint, which is intended to show CaPre’s overall impact on lowering triglycerides (TGs) after 12 weeks compared to placebo. Safety and tolerability (e.g. overall adverse events (AE) and serious AE rate, and any discontinuation due to AEs) will also be reported. Other important secondary endpoints such as Non-HDL cholesterol, HDL cholesterol, and VLDL may now also be reported with the topline results. As previously disclosed, subgroup analyses of certain key secondary (LDL) and exploratory markers (HbA1c) will be dependent on combining results from both studies, and would be expected sometime later in the first quarter of 2020.
- Pursuant to the November ATM Distribution, Acasti issued an aggregate of 2,628,263 common shares of the Company (the “ATM Shares”) over the NASDAQ Stock Market for aggregate gross proceeds to the Company of US$5,693,057.27. The ATM Shares were sold at prevailing market prices which ranged from US$2.05 per share to US$2.27 per share.
- Acasti believes that EPA and DHA are more efficiently transported by phospholipids sourced from krill oil than the EPA and DHA contained in fish oil that are transported either by triglycerides (as in dietary supplements) or as ethyl esters in other prescription omega-3 drugs, which must then undergo additional digestion before they are ready for transport in the bloodstream. Clinically, the phospholipids may not only improve the absorption, distribution, and metabolism of omega-3s, but they may also decrease the synthesis of LDL cholesterol in the liver, impede or block cholesterol absorption, and stimulate lipid secretion from bile.
Buen dia para todos por aqui
framus . al final aunque no lo parecia, pero se comporto como Doble techo , el AT es asi
mugi . mi opinion , manipulacion total , tenian un ATM en marcha y necesitan fondos, la pumpearon por todos lados, un descaro mas
0tra probabilidad-- Los Trilogy 1 y 2 han sido exitosos, ,conviene soltar los dos read out a la vez , y unos pejes gordos quieren entrar a precios muy atractivos, entonces interesa , el delay con su consecuente sell off, inventos mios claro.
Yo, en cuanto defina suelo, re compro la mitad que solte a 2.50 y me apunto al segundo rally que de aqui a finales de enero debe haber , probablemente espere la correccion del SP que espero para enero tambien para hacer esa re compra , y de ser asi , a saco pues si o si rally ACST de aqui a finales de enero vamos a tener, La mitad que me quedo le voy a poner un SLoss en breakeven y si se vende y luego baja mas re compro otra vez
Sigo pensando que aunque tal vez no sea mejor que Vascepa ni tiene aun los estudios de esta para competir pero la molecula del Ac Krilll funciona ,hace años esta en el mercado de forma impirica y con buena biotolerancia, pero le queda mucho camino a ACST entonces ,asi que me apunto a largo, Plan Inversor y cada vez que se pueda a tradear
Mas opiniones se agradecen tambien
-----------.
- Topline results will include a readout of the primary endpoint, which is intended to show CaPre’s overall impact on lowering triglycerides (TGs) after 12 weeks compared to placebo. Safety and tolerability (e.g. overall adverse events (AE) and serious AE rate, and any discontinuation due to AEs) will also be reported. Other important secondary endpoints such as Non-HDL cholesterol, HDL cholesterol, and VLDL may now also be reported with the topline results. As previously disclosed, subgroup analyses of certain key secondary (LDL) and exploratory markers (HbA1c) will be dependent on combining results from both studies, and would be expected sometime later in the first quarter of 2020.
- Pursuant to the November ATM Distribution, Acasti issued an aggregate of 2,628,263 common shares of the Company (the “ATM Shares”) over the NASDAQ Stock Market for aggregate gross proceeds to the Company of US$5,693,057.27. The ATM Shares were sold at prevailing market prices which ranged from US$2.05 per share to US$2.27 per share.
- Acasti believes that EPA and DHA are more efficiently transported by phospholipids sourced from krill oil than the EPA and DHA contained in fish oil that are transported either by triglycerides (as in dietary supplements) or as ethyl esters in other prescription omega-3 drugs, which must then undergo additional digestion before they are ready for transport in the bloodstream. Clinically, the phospholipids may not only improve the absorption, distribution, and metabolism of omega-3s, but they may also decrease the synthesis of LDL cholesterol in the liver, impede or block cholesterol absorption, and stimulate lipid secretion from bile.
